| Identification | Back Directory | [Name]
MDL 101146 | [CAS]
149859-17-6 | [Synonyms]
146
MD 101
MDL 101
MDL-101
MD 101,146
MDL 101146
L-Prolinamide, N-[4-(4-morpholinylcarbonyl)benzoyl]-L-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]- (9CI) | [Molecular Formula]
C29H37F5N4O6 | [MDL Number]
MFCD00918032 | [MOL File]
149859-17-6.mol | [Molecular Weight]
632.62 |
| Hazard Information | Back Directory | [Uses]
MDL 101146 is an orally active neutrophil elastase inhibitor. MDL 101146 inhibits neutrophil elastase for human with a Ki value of 25 nM. MDL 101146 can be used for the research of arthritis[1][2]. | [in vivo]
MDL 101146 (oral, 200 mg/kg/day) significantly inhibits swelling and joint destruction in collagen-induced arthritis but not in adjuvant arthritis[2]. | Animal Model: | Rats[2] | | Dosage: | 200 mg/kg | | Administration: | Oral, 200 mg/kg/day | | Result: | Inhibited the severity of collagen-induced arthritis.
Had a bone and cartilage sparing effect in the tibio-tarsal joint of animals with collagen-induced arthritis.
|
| [References]
[1] Angelastro M, et al. Inhibition of human neutrophil elastase with peptidyl DOI:10.1021/jm00052a013
[2] M J Janusz, et al. Inhibition of cartilage degradation in rat collagen-induced arthritis but not adjuvant arthritis by the neutrophil elastase inhibitor MDL 101,146. Inflamm Res. 1997 Dec;46(12):503-8. DOI:10.1007/s000110050233 |
|
|